High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity
Cardiovascular disease and cancer are the leading causes of death in developed societies. Despite their effectiveness, many cancer therapies exhibit deleterious cardiovascular side effects such as cardiotoxicity and heart failure. The cardiotoxic effects of anthracyclines such as doxorubicin are the...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-04-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fcvm.2020.00065/full |
_version_ | 1818901996770426880 |
---|---|
author | George E. G. Kluck Kristina K. Durham Jeong-Ah Yoo Bernardo L. Trigatti |
author_facet | George E. G. Kluck Kristina K. Durham Jeong-Ah Yoo Bernardo L. Trigatti |
author_sort | George E. G. Kluck |
collection | DOAJ |
description | Cardiovascular disease and cancer are the leading causes of death in developed societies. Despite their effectiveness, many cancer therapies exhibit deleterious cardiovascular side effects such as cardiotoxicity and heart failure. The cardiotoxic effects of anthracyclines such as doxorubicin are the most well-characterized of cardiotoxic anti-cancer therapies. While other anti-neoplastic drugs also induce cardiotoxicity, often leading to heart failure, they are beyond the scope of this review. This review first summarizes the mechanisms of doxorubicin-induced cardiotoxicity. It then reviews emerging preclinical evidence that high density lipoprotein and its precursor protein apolipoprotein A1, which are known for their protective effects against ischemic cardiovascular disease, may also protect against doxorubicin-induced cardiotoxicity both directly and indirectly, when used therapeutically. |
first_indexed | 2024-12-19T20:28:38Z |
format | Article |
id | doaj.art-094439669c184bbf882a618d79fc0e6a |
institution | Directory Open Access Journal |
issn | 2297-055X |
language | English |
last_indexed | 2024-12-19T20:28:38Z |
publishDate | 2020-04-01 |
publisher | Frontiers Media S.A. |
record_format | Article |
series | Frontiers in Cardiovascular Medicine |
spelling | doaj.art-094439669c184bbf882a618d79fc0e6a2022-12-21T20:06:47ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2020-04-01710.3389/fcvm.2020.00065520477High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated CardiotoxicityGeorge E. G. Kluck0Kristina K. Durham1Jeong-Ah Yoo2Bernardo L. Trigatti3Department of Biochemistry and Biomedical Sciences, Thrombosis and Atherosclerosis Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, CanadaFaculty of Health Sciences, Institute of Applied Health Sciences, School of Rehabilitation Sciences, McMaster University, Hamilton, ON, CanadaDepartment of Biochemistry and Biomedical Sciences, Thrombosis and Atherosclerosis Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, CanadaDepartment of Biochemistry and Biomedical Sciences, Thrombosis and Atherosclerosis Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, CanadaCardiovascular disease and cancer are the leading causes of death in developed societies. Despite their effectiveness, many cancer therapies exhibit deleterious cardiovascular side effects such as cardiotoxicity and heart failure. The cardiotoxic effects of anthracyclines such as doxorubicin are the most well-characterized of cardiotoxic anti-cancer therapies. While other anti-neoplastic drugs also induce cardiotoxicity, often leading to heart failure, they are beyond the scope of this review. This review first summarizes the mechanisms of doxorubicin-induced cardiotoxicity. It then reviews emerging preclinical evidence that high density lipoprotein and its precursor protein apolipoprotein A1, which are known for their protective effects against ischemic cardiovascular disease, may also protect against doxorubicin-induced cardiotoxicity both directly and indirectly, when used therapeutically.https://www.frontiersin.org/article/10.3389/fcvm.2020.00065/fullHDLApoA1anthracyclinchemotherapycardiotoxicitycardioprotective |
spellingShingle | George E. G. Kluck Kristina K. Durham Jeong-Ah Yoo Bernardo L. Trigatti High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity Frontiers in Cardiovascular Medicine HDL ApoA1 anthracyclin chemotherapy cardiotoxicity cardioprotective |
title | High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity |
title_full | High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity |
title_fullStr | High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity |
title_full_unstemmed | High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity |
title_short | High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity |
title_sort | high density lipoprotein and its precursor protein apolipoprotein a1 as potential therapeutics to prevent anthracycline associated cardiotoxicity |
topic | HDL ApoA1 anthracyclin chemotherapy cardiotoxicity cardioprotective |
url | https://www.frontiersin.org/article/10.3389/fcvm.2020.00065/full |
work_keys_str_mv | AT georgeegkluck highdensitylipoproteinanditsprecursorproteinapolipoproteina1aspotentialtherapeuticstopreventanthracyclineassociatedcardiotoxicity AT kristinakdurham highdensitylipoproteinanditsprecursorproteinapolipoproteina1aspotentialtherapeuticstopreventanthracyclineassociatedcardiotoxicity AT jeongahyoo highdensitylipoproteinanditsprecursorproteinapolipoproteina1aspotentialtherapeuticstopreventanthracyclineassociatedcardiotoxicity AT bernardoltrigatti highdensitylipoproteinanditsprecursorproteinapolipoproteina1aspotentialtherapeuticstopreventanthracyclineassociatedcardiotoxicity |